Technical Analysis for BNTC - Benitec Biopharma Limited

Grade Last Price % Change Price Change
grade F 1.69 -1.74% -0.03
BNTC closed down 1.74 percent on Friday, May 24, 2019, on 1.77 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: May 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BNTC trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Calm After Storm Range Contraction -1.74%
BB Squeeze Ended Range Expansion -1.74%
180 Bearish Setup Bearish Swing Setup -1.74%
Bollinger Band Squeeze Range Contraction -1.74%

Older signals for BNTC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering HIV/Aids Wet Age Related Macular Degeneration Hepatitis B Hepatitis C Huntington's Disease Retinitis Pigmentosa RNA Clinical Applications Oculopharyngeal Muscular Dystrophy Chronic And Life Threatening Conditions
Is BNTC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.9
52 Week Low 1.01
Average Volume 5,835
200-Day Moving Average 2.1059
50-Day Moving Average 1.8923
20-Day Moving Average 1.8751
10-Day Moving Average 1.8247
Average True Range 0.1161
ADX 16.35
+DI 18.835
-DI 29.0068
Chandelier Exit (Long, 3 ATRs ) 1.6816
Chandelier Exit (Short, 3 ATRs ) 1.9283
Upper Bollinger Band 2.055
Lower Bollinger Band 1.6952
Percent B (%b) -0.01
BandWidth 19.18831
MACD Line -0.0423
MACD Signal Line -0.0177
MACD Histogram -0.0247
Fundamentals Value
Market Cap 17.33 Million
Num Shares 10.3 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -3.25
Price-to-Sales 3.15
Price-to-Book 1.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.75
Resistance 3 (R3) 1.76 1.74 1.74
Resistance 2 (R2) 1.74 1.73 1.74 1.74
Resistance 1 (R1) 1.72 1.72 1.71 1.71 1.73
Pivot Point 1.70 1.70 1.70 1.70 1.70
Support 1 (S1) 1.68 1.69 1.67 1.67 1.65
Support 2 (S2) 1.66 1.68 1.66 1.64
Support 3 (S3) 1.64 1.66 1.64
Support 4 (S4) 1.63